Hochmair MJ, Prosch H, Krenbek D, Weinlinger C, Fabikan H, Valipour A. (2020). Alectinib following brigatinib: an efficient sequence for the treatment of advanced anaplastic lymphoma kinase-positive lung cancer patients. Anticancer Drugs, [e-pub ahead a print] (writing assistance). 

F. Boulmé. DFP-Literaturstudium: “Real World Evidence”. CliniCum Onko, Medizin Medien Austria, September 2020. (

F. Boulmé. Positionspapier: Brauchen wir eine Modifikation der mRCC Therapie unter COVID 19? Virtuelles Expertenmeeting, RCC Academy, August 2020. (

F. Boulmé. medonline: Onko News (Beiträge). (2020). (

F. Boulmé. DFP-Literaturstudium: “Precision Oncology”. CliniCum Onko, Medizin Medien Austria, April 2020. (

F. Boulmé. “Lungenkrebs: Todesursache Nummer eins“. Ärzte Woche (9), Springer-Verlag, Februar 2020. (


S. Beirer, W. Grisold, J. Dreisbach. (2020). ”Therapy-resistant dysphagia successfully treated using pharyngeal electrical stimulation in a patient with the pharyngeal-cervical-brachial variant of the Guillain-Barré syndrome”. eNeurologicalSci. 20:100255 (writing assistance).


F. Boulmé. “Empfehlungen für die Intensivtherapie von SARS-CoV-2 positiven Patienten“. Ärzte Woche (17), Springer-Verlag, April 2020.

F. Boulmé. DFP-Literaturstudium: “SARS-CoV-2 im Wartezimmer“. Ärzte Woche (12), Springer-Verlag, März 2020. (

F. Freund, F. Boulmé, S. Litvak, L. Tarrago-Litvak. (2001) “Initiation of HIV-2 reverse transcription: a secondary structure model of the RNA-tRNA(Lys3) duplex“. Nucleic Acids Res., 29, 2757-65.

F. Freund, F. Boulmé, J. Michel, M. Ventura, S. Moreau, S. Litvak. (2001) “Inhibition of HIV-1 replication in vitro and in human infected cells by modified antisense oligonucleotides targeting the tRNALys3/RNA initiation complex“. Antisense Nucleic Acid Drug. Dev., 11, 301-15.

S. Litvak, M.-L. Andréola, F. Boulmé, F. Freund, R. El-Dirani, E. Dufour, M. Ventura, L. Tarrago-Litvak. (2001) “Reverse transcriptase of HIV-1: novel therapeutic interventions” in “Pharmacology of HIV infection and AIDS”, edited by Dietmar Fuchs, OICA International Press, Saint-Lucia, London.

F. Boulmé, F. Freund, S. Gryaznov, P. E. Nielsen, L. Tarrago-Litvak, S. Litvak. (2000) “Study of HIV-2 primer-template initiation complex using antisense oligonucleotides“. Eur. J. Biochem., 267, 2803-11.

B. Mestre, A. Arzumanov, M. Singh, F. Boulmé, S. Litvak, M. J. Gait. (1999) “Oligonucleotide inhibition of the interaction of HIV-1 Tat protein with the trans-activation responsive region (TAR) of HIV RNA“. Biochim. Biophys. Acta, 1445, 86-98.

F. Boulmé. “In vitro effect of phosphodiester and chemically modified antisense oligonucleotides on the initiation step of the HIV-1 and HIV-2 reverse transcription”. PhD obtained on the 22nd of June1998, University of Bordeaux II, France.

F. Boulmé, F. Freund, S. Moreau, P. E. Nielsen, S. Gryaznov, J.-J. Toulmé, S. Litvak. (1998) “Modified (PNA, 2’O-methyl and phosphoramidate) anti-TAR antisense oligonucleotides as strong and specific inhibitors of in vitro HIV-1 reverse transcription“. Nucleic Acids Res. 26, 5492-500.

F. Boulmé, F. Freund, S. Litvak. “Initiation of in vitro reverse transcription from tRNALys3 on HIV-1 and HIV-2 RNAs by both type 1 and type 2 reverse transcriptases“. (1998) FEBS Letters, 430, 165-70.

E. Dufour, R. El Dirani-Diab, F. Boulmé, M. Fournier, G. Nevinsky, L. Tarrago-Litvak, S. Litvak, M.-L. Andreola. (1998) “p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1: interactions with primer tRNALys3, initiation of cDNA synthesis and effect of inhibitors“. Eur. J. Biochem., 251, 487-95.

F. Boulmé, M. Perälä-Heape, L. Sarih-Cottin, S. Litvak. (1997) “Specific inhibition of in vitro reverse transcription using antisense oligonucleotides targeted to the TAR regions of HIV-1 and HIV-2″. Biochim. Biophys. Acta, 1351, 249-55.


*Erste Co-Autorin

B. Pradet-Balade, C. Leberbauer, N. Schweifer, F. Boulmé. (2010) “Massive translational repression of gene expression during mouse erythroid differentiation“. Biochim. Biophys. Acta, 1799, 630-41.

C. Leberbauer, *F. Boulmé, G. Unfried, J. Huber, H. Beug, E. Müllner. (2005) “Different steroids co-regulate long-term expansion versus terminal differentiation in primary human erythroid progenitors“. Blood, 105, 85-94.

M. Joosten, M. Blazquez-Domingo, F. Lindeboom, *F. Boulmé, A. Van Hoven-Beijen, B. Habermann, B. Löwenberg, H. Beug, E. W. Müllner, R. Delwel, M. Von Lindern. (2004) “Translational control of putative proto-oncogene Nm23-M2 by cytokines via phosphoinositide 3-kinase signaling”. J. Biol. Chem., 279, 38169-76.

H. Dolznig, F. Boulmé, K. Stangl, E. M. Deiner, W. Mikulits, H. Beug, E. W. Mülllner. (2001) “Establishment of normal, terminally differentiating mouse erythroid progenitors: molecular characterization by cDNA arrays“. FASEB J., 15, 1442-4

Translation Kontrolle

B. Pradet-Balade, F. Boulmé, H. Beug, E. W. Müllner, J. A. Garcia-Sanz. (2001) “Translation control: bridging the gap between genomics and proteomics?“. Trends Biochem. Sci., 26, 225-9.

B. Pradet-Balade, F. Boulmé, E. W. Müllner, J. A. Garcia-Sanz. (2001) “Reliability of mRNA profiling: verification for samples with different complexities“. Biotechniques, 30, 1352-7.